Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry

Biomarkers

Volumn 17, Issue 2, 2012, Pages 125-133

  Wu, Jiang ^a   Pungaliya, Pooja ^a   Kraynov, Eugenia ^a   Bates, Brian ^a  

^a PFIZER INC   (United States)

Author keywords

MRMMS; NSCLC; Osteopontin; Plasma; Splice variant

Indexed keywords

ISOPROTEIN; OSTEOPONTIN; OSTEOPONTIN A; OSTEOPONTIN B; OSTEOPONTIN C; UNCLASSIFIED DRUG;

ARTICLE; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; NORMAL HUMAN; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CELL LINE, TUMOR; EXONS; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MASS SPECTROMETRY; MOLECULAR SEQUENCE DATA; OSTEOPONTIN; PEPTIDE FRAGMENTS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RNA, NEOPLASM; UNITED STATES;

EID: 84863229203     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.643485     Document Type: Article

References (38)

1. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO, Al-Katib W, Stitt LW, Uede T, Chambers AF, Tuck AB. (2006). Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol 169:233-246.
2. Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF. (2009). New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs. Clin Chem 55:895-903.
3. Banerjee A, Lee JH, Ramaiah SK. (2008). Interaction of osteopontin with neutrophil α(4)β(1) and α(9)β(1) integrins in a rodent model of alcoholic liver disease. Toxicol Appl Pharmacol 233:238-246.
4. Blasberg JD, Goparaju CM, Pass HI, Donington JS. (2010a) Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity. J Torac Cardiovasc Surg 139:1587-1593.
5. Blasberg JD, Pass HI, Goparaju CM, Flores RM, Lee S, Donington JS. (2010b) Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer. J Clin Oncol 28:936-941.
6. Chae S, Jun HO, Lee EG, Yang SJ, Lee DC, Jung JK, Park KC, Yeom YI, Kim KW. (2009). Osteopontin splice variants diferentially modulate the migratory activity of hepatocellular carcinoma cell lines. Int J Oncol 35:1409-1416.
7. Chang YS, Kim HJ, Chang J, Ahn CM, Kim SK, Kim SK. (2007). Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373-380. (Pubitemid 47285428)
8. Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sørensen ES. (2007). Cell type-specifc post-translational modifcations of mouse osteopontin are associated with diferent adhesive properties. J Biol Chem 282:19463-19472. (Pubitemid 47100061)
9. Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sørensen ES. (2005). Post-translationally modifed residues of native human osteopontin are located in clusters: identifcation of 36 phosphorylation and fve O-glycosylation sites and their biological implications. Biochem J 390:285-292. (Pubitemid 41192254)
10. Christensen B, Petersen TE, Sørensen ES. (2008). Post-translational modifcation and proteolytic processing of urinary osteopontin. Biochem J 411:53-61. (Pubitemid 351482346)
11. Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT. (2010). Te RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS ONE 5:e9633.
12. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW. (2011). Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best? Lung Cancer 74:55-60.
13. Goparaju CM, Pass HI, Blasberg JD, Hirsch N, Donington JS. (2010). Functional heterogeneity of osteopontin isoforms in non-small cell lung cancer. J Torac Oncol 5:1516-1523.
14. He B, Mirza M, Weber G F. (2006). An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 25:2192-2202.
15. Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, Pass HI. (2009). Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382:514-518.
16. Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. (2007). Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ter Targets 11:81-90. (Pubitemid 46099754)
17. Kazanecki CC, Uzwiak DJ, Denhardt DT. (2007). Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem 102:912-924. (Pubitemid 350036931)
18. Keykhosravani M, Doherty-Kirby A, Zhang C, Brewer D, Goldberg HA, Hunter GK, Lajoie G. (2005). Comprehensive identifcation of post-translational modifcations of rat bone osteopontin by mass spectrometry. Biochemistry 44:6990-7003. (Pubitemid 40632417)
19. Kiernan UA, Phillips DA, Trenchevska O, Nedelkov D. (2011). Quantitative mass spectrometry evaluation of human retinol binding protein 4 and related variants. PLoS ONE 6:e17282.
20. Kuhn E, Addona T, Keshishian H, Burgess M, Mani DR, Lee RT, Sabatine MS, Gerszten RE, Carr SA. (2009). Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoafnity enrichment and targeted mass spectrometry. Clin Chem 55:1108-1117.
21. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. (2004). Quantifcation of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 4:1175-1186. (Pubitemid 38445974)
22. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR; SWOG. (2008). Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26:4771-4776.
23. Makawita S, Diamandis EP. (2010). Te bottleneck in the cancer biomarker pipeline and protein quantifcation through mass spectrometry-based approaches: current strategies for candidate verifcation. Clin Chem 56:212-222.
24. Meng Z, Veenstra TD. (2011) Targeted mass spectrometry approaches for protein biomarker verifcation. J Proteomics 74:2650.
25. Mi Z, Guo H, Wai PY, Gao C, Wei J, Kuo PC. (2004). Diferential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem 279:46659-46667. (Pubitemid 39518312)
26. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, Weber GF. (2008). Osteopontin-c is a selective marker of breast cancer. Int J Cancer 122:889-897.
27. Nicol GR, Han M, Kim J, Birse CE, Brand E, Nguyen A, Mesri M, FitzHugh W, Kaminker P, Moore PA, Ruben SM, He T. (2008). Use of an immunoafnity-mass spectrometry-based approach for the quantifcation of protein biomarkers from serum samples of lung cancer patients. Mol Cell Proteomics 7:1974-1982.
28. Ocaña MF, Neubert H. (2010). An immunoafnity liquid chromatography-tandem mass spectrometry assay for the quantitation of matrix metalloproteinase 9 in mouse serum. Anal Biochem 399:202-210.
29. Paleari L, Rotolo N, Imperatori A, Puzone R, Sessa F, Franzi F, Meacci E, Camplese P, Cesario A, Paganuzzi M. (2009). Osteopontin is not a specifc marker in malignant pleural mesothelioma. Int J Biol Markers 24:112-117.
30. Plumer A, Duan H, Subramaniam S, Lucas FL, Miesfeldt S, Ng AK, Liaw L. (2008). Development of fragment-specifc osteopontin antibodies and ELISA for quantifcation in human metastatic breast cancer. BMC Cancer 8:38.
31. Rangaswami H, Bulbule A, Kundu GC. (2006). Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79-87. (Pubitemid 43247403)
32. Shakey Q, Bates B, Wu J. (2010). An approach to quantifying N-linked glycoproteins by enzyme-catalyzed 18O3-labeling of solid-phase enriched glycopeptides. Anal Chem 82:7722-7728.
33. Sullivan J, Blair L, Alnajar A, Aziz T, Ng CY, Chipitsyna G, Gong Q, Witkiewicz A, Weber GF, Denhardt DT, Yeo CJ, Arafat HA. (2009). Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma. Surgery 146:232-240.
34. Tilli TM, Franco VF, Robbs BK, Wanderley JL, da Silva FR, de Mello KD, Viola JP, Weber G F, Gimba ER. (2011). Osteopontin-c splicing isoform contributes to ovarian cancer progression. Mol Cancer Res 9:280-293.
35. Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M. (2006). Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6:207.
36. Wai PY, Kuo PC. (2008). Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27:103-118.
37. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S. (2002). Phosphorylation-dependent interaction of osteopontin with its receptors regulates macrophage migration and activation. J Leukoc Biol 72:752-761. (Pubitemid 36277847)
38. Zhao B, Sun T, Meng F, Qu A, Li C, Shen H, Jin Y, Li W. (2011). Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer. J Cancer Res Clin Oncol 137:1061-1070.